Agile Therapeutics, Inc. (AGRX) Stock Overview
Explore Agile Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Agile Therapeutics, Inc. (AGRX)
Key Financials
Key Financials
Market Cap
10.4M
P/E Ratio
-0.23
EPS (TTM)
$-1.70
ROE
1.32%
AGRX Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Agile Therapeutics, Inc. (NASDAQ: AGRX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Agile Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of AGRX on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $268.63 for the NASDAQ listing.
Key metrics behind Agile Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -0.23 and a market capitalization of 10.4M. Combined with our AI analysis, these give both institutional and retail investors a clear view of AGRX on the NASDAQ.